By staff writers

December 7, 2018 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has received a patent extension for its Lymphoseek radiopharmaceutical.

The company reported that the U.S. Patent and Trademark Office has extended the duration of U.S. patent No. 6,409,990 for another five years, until May 2025. The patent covers the technology behind Lymphoseek, a technetium-based radiopharmaceutical that has been licensed to Cardinal Health.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking